Items where authors include "McInnes, I"

Article

Coates, LC, Garrood, T, Gullick, N et al. (8 more authors) (2022) Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC. Rheumatology. ISSN 1462-0324

Alunno, A, Najm, A, Machado, PM et al. (21 more authors) (2021) EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. Annals of the Rheumatic Diseases. ISSN 0003-4967

Nash, P, Kerschbaumer, A, Dörner, T et al. (26 more authors) (2021) Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the Rheumatic Diseases, 80 (1). pp. 71-87. ISSN 0003-4967

Smolen, JS, Landewé, R, Bijlsma, J et al. (46 more authors) (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 76 (6). pp. 960-977. ISSN 0003-4967

Conference or Workshop Item

Rahman, P, Ritchlin, C, Mease, P et al. (10 more authors) (2022) Long-term Safety of Guselkumab in Patients With Active Psoriatic Arthritis: Pooled Results From 3 Randomized Clinical Trials Through Up to 2 Years. In: Open Access Canadian Rheumatology Association Annual Meeting, 02-05 Feb 2022, Online.

Rahman, P, Ritchlin, C, Mease, P et al. (11 more authors) (2021) Long-term Safety of Guselkumab (TREMFYA (R)) in Patients with Active Psoriatic Arthritis: Pooled Results from 3 Randomized Clinical Trials Through up to 2 Years. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Ritchlin, CT, Rahman, P, Helliwell, PS orcid.org/0000-0002-4155-9105 et al. (7 more authors) (2021) Safety of guselkumab in patients with psoriatic arthritis through 1 year: Pooled findings from DISCOVER-1 and DISCOVER-2 phase 3 trials. In: AAD VMX 2021, 23-25 Apr 2021, Virtual.

Coates, LC, Garrood, T, Gullick, N et al. (8 more authors) (2021) Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC. In: British Society for Rheumatology Annual Conference 2021, 26-28 Apr 2021, Virtual.

Rahman, P, Ritchlin, C, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (12 more authors) (2021) Integrated Safety Results of Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis through the Placebo-Controlled Periods. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.

Proceedings Paper

McInnes, I, Mease, P, Hjuler, KF et al. (2 more authors) (2019) Brodalumab in psoriatic arthritis (PsA): 24-week results from the phase III AMVISON-1 and -2 trials. In: Journal of the American Academy of Dermatology. AAD 2019: American Academy of Dermatology Annual Meeting, 01-05 Mar 2019, Washington, DC, USA. Elsevier , AB28-AB28.